Actively Recruiting
Research for Plasma Biomarkers Associated With Fatigue in Thrombocytopenic Patients
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2026-02-03
280
Participants Needed
1
Research Sites
169 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Thrombocytopenia is a clinical problem defined by a platelet count lower than 150×10⁹/L. It can be linked to various pathologies of central origin, such as decreased platelet production in the bone marrow, or peripheral origin with increased platelet destruction through autoimmune mechanisms, increased splenic sequestration, or excessive platelet consumption. Significant fatigue is often reported in association with thrombocytopenia, but its underlying pathophysiology remains unclear. One hypothesis is the role played by neurotrophic factors contained in platelets and released into the circulation following their activation, in particular the Brain-Derived Neurotrophic Factor (BDNF), which promotes the survival, growth, differentiation, and plasticity of neurons in both the central and peripheral nervous systems. Consequently, BDNF plays a key role in long-term memory, intellectual abilities, and neuroprotection. In this context, this project aims to confirm whether platelet-origin neurotrophic biomarkers could explain the fatigue experienced by thrombocytopenic patients and whether it depends on the etiology of the thrombocytopenia.
CONDITIONS
Official Title
Research for Plasma Biomarkers Associated With Fatigue in Thrombocytopenic Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with constitutional or autoimmune thrombocytopenia (platelet count < 150×10⁹/L) already diagnosed
- Patients not treated with serotonin reuptake inhibitors (SSRIs), norepinephrine reuptake inhibitors (SNRIs), or antithrombotic treatments in the 10 days before inclusion
- Affiliation to social security (beneficiary or assignee)
- Patients followed in consultation in one of the recruiting hematology departments
- Patients or guardians who have received detailed explanation and signed consent
- Age- (± 5 years) and sex-matched healthy adult controls
- Non-thrombocytopenic healthy adults not receiving antithrombotic, SNRI, or SSRI therapy or with last treatment ≥ 10 days
- Healthy adults who have received detailed explanation and signed consent
You will not qualify if you...
- Adult patients under legal protection (guardianship or curatorship)
- Thrombocytopenic patients treated with antithrombotics, SSRIs, or SNRIs
- Minor patients weighing less than 20 kg
- Healthy adult volunteers under legal protection (guardianship, curatorship, or safeguard of justice)
- Pregnant women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hôpital Bichat-Claude Bernard
Paris, France, 75018
Actively Recruiting
Research Team
N
Nadine Ajzenberg
CONTACT
G
Georges Jourdi
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here